Latest news with #AlumisInc
Globe and Mail
08-04-2025
- Business
- Globe and Mail
Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Psoriasis Pipeline Insight 2025 ' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Psoriasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Psoriasis Pipeline Outlook Key Takeaways from the Psoriasis Pipeline Report In April 2025, Alumis Inc. announced a study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001. Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. DelveInsight's Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment. The leading Psoriasis Companies such as Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals and others. Promising Psoriasis Pipeline Therapies such as Hypericin, Cetaphil, EDP1815, AX-158, Calcipotriol, MP1032, Risankizumab, Certolizumab Pegol, and others. Stay ahead with the most recent pipeline outlook for Psoriasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Psoriasis Treatment Drugs Psoriasis Emerging Drugs Profile Topical roflumilast: Arcutis Biotherapeutics Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis. GSK2982772: GlaxoSmithKline GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis. The Psoriasis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment. Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market Explore groundbreaking therapies and clinical trials in the Psoriasis Pipeline. Access DelveInsight's detailed report now! @ New Psoriasis Drugs Psoriasis Companies Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals and others. Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical. Molecule Type Psoriasis Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Psoriasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Psoriasis Market Drivers and Barriers Scope of the Psoriasis Pipeline Report Coverage- Global Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals and others. Psoriasis Pipeline Therapies- Hypericin, Cetaphil, EDP1815, AX-158, Calcipotriol, MP1032, Risankizumab, Certolizumab Pegol, and others. Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Psoriasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Psoriasis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Psoriasis: Overview Pipeline Therapeutics Therapeutic Assessment Psoriasis – DelveInsight's Analytical Perspective In-depth Commercial Assessment Psoriasis Collaboration Deals Late Stage Products (Phase III) CT-P43: Celltrion Drug profiles in the detailed report….. Mid Stage Products (Phase II) EDP1815: Evelo Biosciences Drug profiles in the detailed report….. Early Stage Products (Phase I) AZD0284: AstraZeneca Drug profiles in the detailed report….. Early Stage Products (Preclinical) AZD0284: AstraZeneca Drug profiles in the detailed report….. Inactive Products Psoriasis Key Companies Psoriasis Key Products Psoriasis- Unmet Needs Psoriasis- Market Drivers and Barriers Psoriasis- Future Perspectives and Conclusion Psoriasis Analyst Views Psoriasis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yahoo
05-04-2025
- Business
- Yahoo
Insider Buying: Alumis Independent Director Bought US$130k Of Shares
Potential Alumis Inc. (NASDAQ:ALMS) shareholders may wish to note that the Independent Director, Alan Colowick, recently bought US$130k worth of stock, paying US$7.04 for each share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Notably, that recent purchase by Alan Colowick is the biggest insider purchase of Alumis shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$10.05. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price. While Alumis insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for Alumis There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them). For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Alumis insiders own 1.1% of the company, worth about US$5.0m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing! It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Alumis insiders are reasonably well aligned, and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 4 warning signs (3 shouldn't be ignored!) that you ought to be aware of before buying any shares in Alumis. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Associated Press
07-02-2025
- Business
- Associated Press
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. is fair to Alumis shareholders. Upon closing of the proposed transaction, Alumis shareholders will own approximately 55% of the combined company. Halper Sadeh encourages Alumis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Alumis and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Alumis shareholders; and (2) disclose all material information necessary for Alumis shareholders to adequately assess and value the merger consideration. On behalf of Alumis shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Daniel Sadeh, Esq. Zachary Halper, Esq. SOURCE: Halper Sadeh LLC Copyright Business Wire 2025. PUB: 02/06/2025 09:50 PM/DISC: 02/06/2025 09:52 PM
